Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA 24 FE vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Treatment of dysmenorrhea (off-label),Acne vulgaris (off-label)
Prevention of pregnancy
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily metabolized via CYP3A4. Norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes phase I (hydroxylation via CYP3A4) and phase II (glucuronidation) metabolism.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: ~91% to albumin and SHBG; Ethinyl estradiol: ~97% to albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: ~1.5 L/kg; Ethinyl estradiol: ~15 L/kg. Indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Norethindrone: ~64%; Ethinyl estradiol: ~43% (oral).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Use is not recommended in severe renal impairment or acute renal failure due to potential accumulation of components.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with hepatic impairment or active liver disease. No specific dose adjustments provided for mild impairment; use not recommended in Child-Pugh class B or C.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy established in females of reproductive age post-menarche. Dosing same as adults (0.10 mg/1.0 mg daily for 24 days, then placebo for 4 days).
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No specific dose adjustments required for elderly, but consider risks of thromboembolism and other comorbidities.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Hepatic neoplasia,Gallbladder disease,Hypertension,Hyperkalemia in renal impairment (due to drospirenone component in some formulations; not applicable to this product),Glucose intolerance,Depression,Uterine bleeding irregularities,Follicular atresia and amenorrhea after discontinuation,Contact lens intolerance
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders,History of DVT or PE,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal vaginal bleeding,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Hepatic adenoma or carcinoma,Active liver disease with impaired function,Hypersensitivity to any component,Smoking in women over 35
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No food interactions documented. Grapefruit juice may increase estrogen exposure but not clinically significant; no restriction needed.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and potential for neonatal hepatic dysfunction. Contraindicated in pregnancy due to teratogenicity.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in breast milk in low amounts; M/P ratio not well established. Use during lactation is generally not recommended due to potential adverse effects on infant, including jaundice and hormonal changes. May suppress milk production.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Not applicable; use is contraindicated during pregnancy. No dose adjustment can mitigate fetal risk; immediate discontinuation upon confirmed pregnancy is required.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
AUROVELA 24 FE is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous fumarate placebo. The iron supplement in placebo pills is not bioavailable and does not treat iron deficiency. Counsel that withdrawal bleed typically occurs during the 4th week (iron pills). Missed pills algorithm: if one active pill missed, take as soon as remembered; if two or more missed, take last missed and use backup contraception for 7 days. Induction of CYP3A4 by rifampin, anticonvulsants, St. John's wort may reduce efficacy. Do not prescribe with concomitant hepatitis C therapy containing ombitasvir/paritaprevir/ritonavir due to ALT elevations.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time, preferably after the evening meal to reduce nausea.,The last 7 tablets are brown iron pills; you will have a withdrawal bleed during this time.,If you vomit within 4 hours of taking an active pill, take another active pill from a separate pack.,Missing two or more active pills may require backup contraception (condoms) for 7 days.,Smoking increases risk of serious cardiovascular side effects; avoid smoking while on this medication.,Report any symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA 24 FE vs ALYACEN 1/35, answered by our medical review team.
AUROVELA 24 FE is a Oral Contraceptive that works by Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA 24 FE and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA 24 FE is: One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA 24 FE and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA 24 FE is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and poten. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.